Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe

Abstract The rituximab biosimilar CT‐P10 is approved for the treatment of non‐Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT‐P10 and reference rituximab. However, real‐world data relating to treatment in patients with DLBCL with rituximab biosimilars are limited....

全面介紹

書目詳細資料

Principais autores:	Mark J. Bishton, Gilles Salles, Camille Golfier, Wolfgang Knauf, Monica Bocchia, Deborah Turner, Borhane Slama, Jatinder Harchowal, Scott Marshall, Alberto Bosi, Juan José Bargay Lleonart, Manfred Welslau, SooKyoung Kim, Young N. Lee, Pier L. Zinzani, Kamel Laribi
格式:	Artigo
語言:	Inglês
出版:	Wiley 2023-02-01
叢編:	eJHaem
主題:	biosimilar DLBCL NHL rituximab
在線閱讀:	https://doi.org/10.1002/jha2.593
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!